Abstract:Background: Therapeutic antibody development is one of the fastest growing areas of the pharmaceutical industry. Generating high-quality monoclonal antibodies against a given therapeutic target is crucial for successful drug development. However, due to immune tolerance, making it difficult to generate antibodies using conventional approaches.Methodology/Findings: Mixed four human gastric cancer (GC) cell lines were used as the immunogen in A/J mice; sixteen highly positive hybridoma colonies were selected via fluorescence-activated cell sorting-high throughput screening (FACS-HTS) using a total of 20,000 colonies in sixty-seven 96-well plates against live cells (mixed human GC cells versus human PBMC controls). MS17-57 and control commercial Alkaline Phosphatase (ALP) mAbs were used to confirm the target antigens (Ags), which were identified as ALPs expressed on the GC cell surface through a combination of western blot, immunoprecipitation and mass spectrometry (MS).MS identified the Ags recognized by MS17-57 to be two variants of a secreted ALP, PALP and IALP (Placental and intestinal ALP). These proteins belong to a hydrolase enzyme family responsible for removing phosphate groups from many types of molecules. Immunofluorescence staining using MS17-57 demonstrated higher staining of gastrointestinal (GI) cancer tissues compared to normal GI tissues (P<0.03), and confirmed binding of MS17-57 to be restricted to a functional epitope expressed on the cancer cell surface. Proliferation assays using the PALP/IALP-expressing GC cell lines demonstrated that MS17-57 inhibited cell growth by 32 +/- 8%. Transwell cell migration assays documented that MS17-57 can inhibit PALP/IALP-expressing GI cancer cell migration by 25 +/- 5%. MS17-57 mAb inhibited tumor growth in nude mice.Conclusions: Our findings indicate that PALP and IALP can be ectopically expressed on extracellular matrix of GI cancers, and that MS17-57 directed against PALP/IALP can inhibit GI cancer cells growth and migration in vitro and in vivo. This investigation provides an example of identification of cancer biomarkers representing promising therapeutic targets using mAb generated through a novel HTS technology.

Generation of phage-displayed single chain variable fragments of monoclonal antibody MGd1 recognizing gastric carcinoma

[Production of phage-displayed single chain variable fragments of monoclonal antibody MGb1].

Preparation and Identification of Monoclonal Antibody Against Human Testis Development Related Gene 1

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

[Construction, Expression and Activity of a Single Chain Antibody to Gastric Cancer Cells].

[Mimic Epitope Recognized by Monoclonal Antibody MG7 Against Gastric Cancer Through Screening Phage Displayed Random Peptide Library].

Generation Of Monoclonal Antibody Ms17-57 Targeting Secreted Alkaline Phosphatase Ectopically Expressed On The Surface Of Gastrointestinal Cancer Cells

Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study

A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms

Selection and Characterization of a Peptide Specifically Targeting to Gastric Cancer Cell Line SGC-7901 Using Phage Display

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer.

Molecular Cloning of a Tumor-Associated Antigen Recognized by Monoclonal Antibody 3H11

Monoclonal Antibodies Against Human Gastric Cancer

An antibody‐drug conjugate targeting a GSTA glycosite‐signature epitope of MUC1 expressed by non‐small cell lung cancer

THE RECOMBINANT ANTI-MAGE-A1 IMMUNOTOXIN INHIBITED THE GROWTH OF HEPTACELLULAR CARCINOMA CELL BEL7402

[Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].

Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique

Cloning of the Cdna Fragment of a Tumor Associated Antigen Recognized by Monoclonal Antibody 3H11

Selection and Characterization of Human Anti-MAGE-A1 Scfv and Immunotoxin

Selection of a Specific Binding Peptide Targeting to Blood Vessel of Human Gastric Cancer in Vivo and Modeling of Its Three Dimensional Structure